What We're Reading: Page
Industry reads hand-picked by our editors
Jul 16, 2026
-
The Economist
Eli Lilly is reinventing the pharma business
-
Bloomberg
Kalshi Will Offer Sports-Style Betting on Drug Trial Results
-
The Washington Post
CDC nominee says she won’t betray science — and also backs Kennedy’s actions
-
BioCentury
Nearly 40% of this year’s Asia-to-West NewCos are aiming at first in class
Jul 15, 2026
Jul 14, 2026
Jul 13, 2026
-
The Financial Times
AstraZeneca CEO: ‘Biology will catch up with me at some point’
-
CNBC
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
-
NBC News
Dozens hospitalized with cyclosporiasis as cases of gastrointestinal illness spike in 31 states
Jul 10, 2026
-
The Wall Street Journal
U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China
-
The Atlantic
The Genes That Could Cancel Out a Fatal Diagnosis
-
Bloomberg
Biotech M&A Surge Seen as Going Beyond Blockbuster Deals
Jul 09, 2026
Jul 08, 2026
-
The New York Times
Plaintiff for Anti-Vaccine Group’s Suit Is Charged With Murder of Her Twins
-
Fierce Biotech
As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’
-
CNBC
Employers aren’t expanding coverage of GLP-1 obesity drugs – many are finding ways around it
Previous
